Read more

This stock has lost 75% of its value from its peak. This is a great opportunity! It has shown consistent growth past so many years. The valuation went too high in 2021 - 2022. Now it is at amazing price that can see appreciation for long term. Given high value and decent growth stock the risks are low. Lot of investors were scared and selling that is why we see outsized moves as well as slowing growth creates challenges to justify valuations. But now clueless investors are selling as it has set the downtrend. We buy when others are fearful on the investments that carries amazing value and growth with lower risks.

Read more

Price target - $3.8 to $4.5

End Date - 30 Jun 2025

Read more

Buy Range - $14 to $15.5

Price target - $25 to $27

End Date - 30 Mar 2026

This stock has unique value with decent growth company in healthcare sector which is recession-proof. Buy slow some at market and some with limit order. It had consistently good earnings which are not getting rewarded. Given the good earnings the stock is getting cheaper and cheaper and it should be valued higher. We see it is a great long term opportunity given the scores. Downside risk for this stock is quite low given the profitability. At the same time this stock has very good risk to reward and can give amazing returns. We booked some profits on about all the lots over past 2-3 years.

CPRX at $14.4

Risk - 8.1 / 10 (10 is low risk)

Growth - 8.2 / 10 (10 is high growth)

Value - 8.3 / 10 (10 is high value)

Market Segment - 7.8 / 10 (10 is better segment)

Market expansion - 8.0 / 10 (10 is better expansion)

Overall score - 8.15 / 10

Read more

Let us sell half of our investment in this hyper growth stock. We got 121% returns just within 6 months! We do see several risks in the market along with unrolling of AI hype, there is a deep risk of excessive leverage in the markets. We have made amazing amount of money in last 18 months while last few weeks were not rewarding as growth stocks whether good or bad - almost all of them are falling as the excess leverage has slowly started unwinding.

This hyper growth stock is bouncing back, we stayed away from some hyper growth stocks with moderate to high risk given the market conditions. But given our models have improved so much and we made a lot of profits since past year. Risk takers let us take some calculated risk buying this hyper growth stock which is still down a lot from its peak. Given its solid fundamentals along with hyper growth we expect it go higher irrespective of whether there is recession or not.

📈 Exceptional Financial Performance

• Revenue Growth: In Q2 FY2025, it reported a 60% year-over-year revenue increase to $70 million, surpassing analyst expectations. For Q3, the company projects revenues around $110 million, indicating robust growth momentum.

• Annual Revenue Surge: A record revenue driven by strong demand from AI infrastructure deployments.

📊 Turning profitable at this amazing growth

🧠 Strategic Positioning in the AI Infrastructure Market

📈 Positive Analyst Outlook

• Upgraded Ratings: Analysts have upgraded the stock based on strong earnings and growth prospects.

Read more

Sell AZO at $3850. We partially (50%) had booked the profits on this last year. Let us sell this investment for future better opportunities. We achieved low risk long term 55% returns in 2 years. Given the fear is setting up in the market and sky high valuations we are taking profits for future investments.

Buy Range - $2400 to $2500

Price target - $3100 to $3400

End Date - 30 Dec 2025

AZO is low risk, decent growth, good value. AZO is one of our very long term recommendation which has ok to decent growth. AZO stock did fall about 15% while the earnings were good and guidance is decent. All the companies are experiencing slowing growth however AZO has really good scores and always had been our very long term stock pick. Since we are still sticking more to value it is a great buy for long term.

Risk - 8.3 / 10 (10 is low risk)

Growth - 7.7 / 10 (10 is high growth)

Value - 8.2 / 10 (10 is high value)

Market Segment - 8.1 / 10 (10 is better segment)

Market expansion - 8.0 / 10 (10 is better expansion)

Overall score - 8.15 / 10

Read more

The stock is not getting rewarded for its AI enablement in healthcare. We had amazing success investing in AI infrastructure companies, multiple of them tripled within our recommendation time span beating our estimates. There are some applications where AI can make impact and we don’t like speculation so here it is - a stock with amazing growth backed by value and is enabling AI in healthcare sector. This stock has good growth and is backed by good value. This stock can give us amazing returns at reasonably moderate risk.

Read more

This stock has very good value at the same time it is a low risk investment. It posted amazing earnings last quarter. It has given a good guidance on future sales showing strength and high growth. There is good backlog of orders for earnings to sustain.

This could be an amazing opportunity for good return. Based on our algorithms and scores we see the downside risk is low and limited given the good value.

Read more

We had earnings for this stock today. The earnings were very good and stock jumped 10% to $70.6, however based on the earnings and guidance from the company our prediction for this stock is well above its current price. At the same time this stock has limited downside given its a good value stock. It is in utilities sector that is relatively recession proof. At the same time AI infrastructure demand is helping the utilities sector and it will continue to do so with ups and downs. Ups and downs in the prices is part of investing. Market is expensive so we will continue to buy more value stocks. Over the time those would give good returns until the uncertainty around inflation and interest rates settle down.

• Good dividend payments

• Very positive cash flow

• Good earnings guidance from company

• Slowdown / recession proof investment

Read more

Closing Update : Another blowout earnings from APP. Today we want to book the profits with APP although it had amazing earnings. Although the earnings numbers are amazing our models did spot weakness going forward. It is a good idea to trim APP position slowly. Let us partially sell asAPP has moderately higher risk of downside, let us not get greedy.

App at $51

Read more